GNPX - ジェンプレックス (Genprex Inc.) ジェンプレックス

 GNPXのチャート


 GNPXの企業情報

symbol GNPx
会社名 Genprex Inc (ジェンプレックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Genprex Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform including its initial product candidate Oncoprex immunogene therapy or Oncoprex. The Company’s Oncoprex is lead product candidate is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer including breast head and neck renal cell (kidney) soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells re-establishes pathways for apoptosis.   ジェンプレックスは米国のバイオ医薬品企業。臨床段階で、同社独自「Oncoprex」免疫療法を含むがん治療における遺伝子治療の開発に従事する。同社プラットフォ―ムは、がんを抑制する遺伝子を管理し、静脈内に投与され腫瘍に取り込まれたがん遺伝子が作るたんぱく質を発現する。同技術に関するテキサス大学がんセンタ―の特許を所有。本社はテキサス州オ―スティン。   
本社所在地 1701 Trinity Street Suite 3.322 Austin TX 78712 USA
代表者氏名 J. Rodney Varner J.ロドニー・バナー
代表者役職名 Chairman of the Board Chief Executive Officer Secretary
電話番号 +1 512-708-0155
設立年月日 39904
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.genprex.com
nasdaq_url https://www.nasdaq.com/symbol/gnpx
adr_tso
EBITDA EBITDA(百万ドル) -8.09860
終値(lastsale) 2
時価総額(marketcap) 30075888
時価総額 時価総額(百万ドル) 26.61716
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 14.61562
当期純利益 当期純利益(百万ドル) -8.13689
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Genprex Inc revenues was not reported. Net loss increased from $1.9M to $6.8M. Higher net loss reflects General and administrative increase from $1.8M to $6.6M (expense) Depreciation increase of 51% to $2K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.51.

 GNPXのテクニカル分析


 GNPXのニュース

   Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants  2021/02/09 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
   Genprex Recognizes World Cancer Day  2021/02/04 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
   Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo  2021/01/21 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.
   Genprex to Present at NobleCon17 on January 19  2021/01/14 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET
   Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer  2021/01/13 14:00:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing
   Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants  2021/02/09 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
   Genprex Recognizes World Cancer Day  2021/02/04 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
   Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo  2021/01/21 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.
   Genprex to Present at NobleCon17 on January 19  2021/01/14 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET
   Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer  2021/01/13 14:00:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing
   Genprex Recognizes World Cancer Day  2021/02/04 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
   Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo  2021/01/21 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.
   Genprex to Present at NobleCon17 on January 19  2021/01/14 13:30:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET
   Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer  2021/01/13 14:00:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing
   Genprex Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis  2020/12/31 12:50:00 Stock Market Daily
Genprex announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジェンプレックス GNPX Genprex Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)